Plaque and tangle imaging and cognition in normal aging and Alzheimer's disease
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Amyloid plaques and tau neurofibrillary tangles, the pathological hallmarks of Alzheimer’s disease (AD), begin accumulating in the healthy human brain decades before clinical dementia symptoms can be detected. There is great interest in how this pathology spreads in the living brain and its association with cognitive deterioration. Using MRI-derived cortical surface models and four-dimensional animation techniques, we related cognitive ability to positron emission tomography (PET) signal from 2-(1-{6-[(2-[F-18]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile ([18F]FDDNP), a molecular imaging probe for plaques and tangles. We examined this relationship at each cortical surface point in 23 older adults (10 cognitively intact, 6 with amnestic mild cognitive impairment, 7 with AD). [18F]FDDNP-PET signal was highly correlated with cognitive performance, even in cognitively intact subjects. Animations of [18F]FDDNP signal growth with decreased cognition across all subjects (http://www.loni.ucla.edu/~thompson/FDDNP/video.html) mirrored the classic Braak and Braak trajectory in lateral temporal, parietal, and frontal cortices. Regions in which cognitive performance was significantly correlated with [18F]FDDNP signal include those that deteriorate earliest in AD, suggesting the potential utility of [18F]FDDNP for early diagnosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490
Automatic 3D intersubject registration of MR volumetric data in standardized Talairach space
Collins, D. L., Neelin, P., Peters, T. M., & Evans, A. C. (1994) · Journal of Computer Assisted Tomography · doi:10.1097/00004728-199403000-00005 · Cited by 3,431
Buckner, R. L., Snyder, A. Z., Shannon, B. J., LaRossa, G., Sachs, R., Fotenos, A. F., Sheline, Y. I., Klunk, W. E., Mathis, C. A., Morris, J. C., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2177-05.2005 · Cited by 2,140
Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease
Gómez-Isla, T., Price, J. L., McKeel Jr., D. W., Morris, J. C., Growdon, J. H., & Hyman, B. T. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-14-04491.1996 · Cited by 1,796
Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories
Braak, H., & Braak, E. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00056-0 · Cited by 1,656
Dynamics of Gray Matter Loss in Alzheimer's Disease
Thompson, P. M., Hayashi, K. M., de Zubicaray, G., Janke, A. L., Rose, S. E., Semple, J., Herman, D., Hong, M. S., Dittmer, S. S., Doddrell, D. M., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-03-00994.2003 · Cited by 1,132
Self-citationTangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease
Giannakopoulos, P., Herrmann, F. R., Bussière, T., Bouras, C., Kövari, E., Perl, D. P., Morrison, J. H., Gold, G., & Hof, P. R. (2003) · Neurology · doi:10.1212/01.wnl.0000063311.58879.01 · Cited by 1,118
Bullmore, E. T., Suckling, J., Overmeyer, S., Rabe-Hesketh, S., Taylor, E., & Brammer, M. J. (1999) · IEEE Transactions on Medical Imaging · doi:10.1109/42.750253 · Cited by 1,088
[ 11 C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease
Mintun, M. A., LaRossa, G. N., Sheline, Y. I., Dence, C. S., Lee, S. Y., Mach, R. H., Klunk, W. E., Mathis, C. A., DeKosky, S. T., & Morris, J. C. (2006) · Neurology · doi:10.1212/01.wnl.0000228230.26044.a4 · Cited by 1,036 · cited 1×
“In addition to [ 18 F]FDDNP, PET ligands Pitts- 54 burgh Compound B (PIB) (Buckner et al., 2005; Klunk et al., 55 2004; Mintun et al., 2006) and stilbene (SB-13) (Verhoeff et 56 al., 2004) are both reported to visualize plaques alone.”
Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer’s disease
Small, G. W., Ercoli, L. M., Silverman, D. H. S., Huang, S.-C., Komo, S., Bookheimer, S. Y., Lavretsky, H., Miller, K., Siddarth, P., Rasgon, N. L., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.090106797 · Cited by 790
Self-citationBerg, L., McKeel, D. W., Miller, J. P., Storandt, M., Rubin, E. H., Morris, J. C., Baty, J., Coats, M., Norton, J., Goate, A. M., et al. (1998) · Archives of Neurology · doi:10.1001/archneur.55.3.326 · Cited by 657
Spatial patterns of cortical thinning in mild cognitive impairment and Alzheimer’s disease
Singh, V., Chertkow, H., Lerch, J. P., Evans, A. C., Dorr, A. E., & Kabani, N. J. (2006) · Brain · doi:10.1093/brain/awl256 · Cited by 386
Bouras, C., Hof, P. R., Giannakopoulos, P., Michel, J.-P., & Morrison, J. H. (1994) · Cerebral Cortex · doi:10.1093/cercor/4.2.138 · Cited by 280
Research works printed but not linked: 23
- Agdeppa, 2001, Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease, J. Neurosci., 21, RC189, 10.1523/JNEUROSCI.21-24-j0004.2001 · DOI · Paper page
- Agdeppa, 2001, In vivo and in vitro labeling of plaques and tangles in the brain of an Alzheimer's disease patient: a case study, Ann. Meet. J. Nuclear Med., 42, 65P
- Apostolova, 2006, 3D mapping of mini-mental state examination performance in clinical and preclinical Alzheimer disease, Alzheimer Dis. Assoc. Disord., 20, 224, 10.1097/01.wad.0000213857.89613.10 · DOI · Paper page
- Binder, 2005, Tau, tangles, and Alzheimer's disease, Biochim. Biophys. Acta, 1739, 216, 10.1016/j.bbadis.2004.08.014 · DOI · Paper page
- Castellani, 2006, Antioxidant protection and neurodegenerative disease: the role of amyloid-beta and tau, Am. J. Alzheimers Dis. Other Demen., 21, 126, 10.1177/153331750602100213 · DOI · Paper page
- Hamilton, 1960, A rating scale for depression, J. Neurol. Neurosurg. Psychiat., 23, 56, 10.1136/jnnp.23.1.56 · DOI · Paper page
- Jones, 2006, Differential verbal fluency deficits in the preclinical stages of Alzheimer's disease and vascular dementia, Cortex, 42, 347, 10.1016/S0010-9452(08)70361-7 · DOI
- Klunk, 2004, Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B, Ann. Neurol., 55, 306, 10.1002/ana.20009 · DOI · Paper page
- Lerch, 2005, Focal decline of cortical thickness in Alzheimer's disease identified by computational neuroanatomy, Cereb. Cortex, 15, 995, 10.1093/cercor/bhh200 · DOI · Paper page
- Liu, 2007, High-yield, automated radiosynthesis of 2-(1-{6-[(2-[18F]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile ([18F]FDDNP) ready for animal or human administration, Mol. Imag. Biol., 9, 6, 10.1007/s11307-006-0061-4 · DOI
- Logan, 1996, Distribution volume ratios without blood sampling from graphical analysis of PET data, J. Cereb. Blood Flow Metab., 16, 834, 10.1097/00004647-199609000-00008 · DOI · Paper page
- MacDonald, 2000, Automated 3D extraction of inner and outer surfaces of cerebral cortex from MRI, Neuroimage, 12, 340, 10.1006/nimg.1999.0534 · DOI · Paper page
- McKhann, 1984, Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease, Neurology, 34, 939, 10.1212/WNL.34.7.939 · DOI · Paper page
- Petersen, 2004, Mild cognitive impairment as a diagnostic entity, J. Intern. Med., 256, 183, 10.1111/j.1365-2796.2004.01388.x · DOI · Paper page
- Selkoe, 2001, Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein, J. Alzheimer's Dis., 3, 75, 10.3233/JAD-2001-3111 · DOI · Paper page
- Shattuck, 2001, Magnetic resonance image tissue classification using a partial volume model, Neuroimage, 13, 856, 10.1006/nimg.2000.0730 · DOI · Paper page
- Small, 2006, PET of brain amyloid and tau in mild cognitive impairment, N. Engl. J. Med., 355, 2652, 10.1056/NEJMoa054625 · DOI · Paper page
- Smith, 2002, Fast robust automated brain extraction, Hum. Brain Mapp., 17, 143, 10.1002/hbm.10062 · DOI · Paper page
- Sowell, 2004, Longitudinal mapping of cortical thickness and brain growth in normal children, J. Neurosci., 24, 8223, 10.1523/JNEUROSCI.1798-04.2004 · DOI · Paper page
- Tabert, 2006, Neuropsychological prediction of conversion to Alzheimer disease in patients with mild cognitive impairment, Arch. Gen. Psychiat., 63, 916, 10.1001/archpsyc.63.8.916 · DOI · Paper page
- Thompson, 2004, Mapping cortical change in Alzheimer's disease, brain development, and schizophrenia, Neuroimage, 23, S2, 10.1016/j.neuroimage.2004.07.071 · DOI · Paper page
- Verhoeff, 2004, In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET, Am. J. Geriatr. Psychiat., 12, 584
- Watson, 2005, Physicochemical characteristics of soluble oligomeric A beta and their pathologic role in Alzheimer's disease, Neurol. Res., 27, 869, 10.1179/016164105X49436 · DOI · Paper page
Cited by
Religious Orders Study and Rush Memory and Aging Project
Bennett, D. A., Buchman, A. S., Boyle, P. A., Barnes, L. L., Wilson, R. S., & Schneider, J. A. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179939 · Cited by 1,260
“Thesedataarecomplementedbyclinical-imaging studieswithamyloidandsubsequentlytauPETdata [358–362].”
Raji, C. A., Ho, A. J., Parikshak, N. N., Becker, J. T., Lopez, O. L., Kuller, L. H., Hua, X., Leow, A. D., Toga, A. W., & Thompson, P. M. (2010) · Human Brain Mapping · doi:10.1002/hbm.20870 · Cited by 686
Self-citationTau PET imaging in neurodegenerative tauopathies—still a challenge
Leuzy, A., Chiotis, K., Lemoine, L., Gillberg, P.-G., Almkvist, O., Rodriguez-Vieitez, E., & Nordberg, A. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0342-8 · Cited by 628
Functional brain connectivity using fMRI in aging and Alzheimer’s disease
Dennis, E. L., & Thompson, P. M. (2014) · Neuropsychology Review · doi:10.1007/s11065-014-9249-6 · Cited by 583
Self-citationGogtay, N., & Thompson, P. M. (2010) · Brain and Cognition · doi:10.1016/j.bandc.2009.08.009 · Cited by 347
Self-citation
Metadata
- Authors
- Braskie, M. N., Klunder, A. D., Hayashi, K. M., Protas, H., Kepe, V., Miller, K. J., Huang, S.-C., Barrio, J. R., Ercoli, L. M., Siddarth, P., Satyamurthy, N., Liu, J., Toga, A. W., Bookheimer, S. Y., Small, G. W., & Thompson, P. M.
- Venue
- Neurobiology of Aging
- Publisher
- Elsevier BV
- Published
- 2010-10
- Volume
- 31
- Issue
- 10
- Pages
- 1669-1678
- ISSN
- 0197-4580 (ISSN-L)
- OpenAlex
- W2075342209
- Cited by
- 114
- References
- 14
- FWCI
- 10.03
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Funders
- U.S. Department of Energy (DE-FC03-87-ER60615)
- National Institute of Biomedical Imaging and Bioengineering
- National Institute of Neurological Disorders and Stroke
- Alzheimer's Association
- National Institute on Aging
- Larry L. Hillblom Foundation
- National Institutes of Health (AG13308, AG10123, P01-AG024831, P50 AG 16570, MH52453, MH/AG58156, M01-RR00865)
- National Center for Research Resources
- Ahmanson Foundation
- U.S. National Library of Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.